131922-05-9

Basic information

• Product Name: Piperazine, 2-(trifluoromethyl)- (9CI)
• Synonyms: Piperazine, 2-(trifluoromethyl)- (9CI);2-(Trifluoromethyl)piperazine 95%;Piperazine, 2-(trifluoromethyl)-
• CAS NO: 131922-05-9
• Molecular Formula: C₅H₉F₃N₂
• Molecular Weight: 154.1335696
• Product Categories: PIPERIDINE
• Mol File: 131922-05-9.mol

Chemical Properties

• Melting Point: 94-97℃
• Boiling Point: 145.1°C at 760 mmHg
• Flash Point: 41.5°C
• Appearance: /
• Density: 1.171g/cm³
• Vapor Pressure: 4.94mmHg at 25°C
• Refractive Index: 1.372
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.75±0.40(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: Piperazine, 2-(trifluoromethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 2-(trifluoromethyl)- (9CI)(131922-05-9)
• EPA Substance Registry System: Piperazine, 2-(trifluoromethyl)- (9CI)(131922-05-9)

Safety Data

• Hazard Codes: C,N
• Statements: 34-50/53
• Safety Statements: 6-26-36/37/39-45-60-61
• RIDADR: UN 3263 8 / PGIII
• WGK Germany: 2
• HazardClass: 8
• Hazardous Substances Data: 131922-05-9(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
Piperazine, 2-(trifluoromethyl)(9CI) is used as a research compound for its unique properties, allowing scientists to explore its potential applications and interactions in various chemical reactions and processes.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Piperazine, 2-(trifluoromethyl)(9CI) is used as a building block or intermediate in the synthesis of various drug molecules. Its ability to engage in hydrogen bonding and its structural features make it a promising candidate for the development of new therapeutic agents.
Used in Material Science:
Piperazine, 2-(trifluoromethyl)(9CI) is used as a component in the development of new materials with specific properties, such as improved stability or reactivity, due to its unique chemical structure and bonding capabilities.

InChI:InChI=1/C5H9F3N2/c6-5(7,8)4-3-9-1-2-10-4/h4,9-10H,1-3H2

Upstream product

• 431-35-6 3-bromo-1,1,1-trifluoroacetone 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 167566-34-9 1-benzyl-3-(trifluoromethyl)piperazine 
• 61655-67-2 2-(trifluoromethyl)pyrazine 

Downstream Products

• 886779-69-7 3-(trifluoromethyl)piperazine-1-carboxylic acid tert-butyl ester 
• 1403897-08-4 1-{6-benzyl-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-c]pyridin-1-yl}-2-[(3R)-3-(fluoromethyl)piperazin-1-yl]ethan-1-one 
• 1403897-05-1 1-{6-benzyl-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-c]pyridin-1-yl}-2-[3-(trifluoromethyl)piperazin-1-yl]ethan-1-one 

Relevant articles and documents

2-(Trifluoromethyl)piperazine: synthesis and characterization using NMR and X-ray photoelectron spectroscopy

The synthesis of 2-(trifluoromethyl)piperazine (1) is reported. 1H NMR spectroscopy shows that in the chair-type piperazine ring the CF3 group occupies an equatorial position.X-ray photoelectron spectroscopy of solid 1 reveals that the CF3 group induces a secondary (β) chemical shift of 1.5 eV on the C 1s core binding energy of its nearest neighbour carbon atom.The results are supported by semi-empirical PM3 and HAM/3 calculations.

DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF

Provided herewith are pharmaceutical tablet compositions comprising an organic acid (such as fumaric acid) and a compound of Formula (I), or an N-oxide thereof, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of Formula (I) or N-oxide thereof: wherein the compound of Formula (I) is an inhibitor of Bruton' s tyrosine kinase.

5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.

NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER

The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Antiviral indoleoxoacetyl piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids

7-(substituted)piperazinyl-1-ethyl-6-fluoro-4-oxo-3-quinolinecarboxylic acids, the pharmacologically acceptable salts thereof, compositions containing them, processes and intermediates for producing them, and methods of using them to treat bacterial infections in warm-blooded animals.